264 related articles for article (PubMed ID: 21479688)
21. Expression of multidrug resistance genes in normal and cancer stem cells.
Shervington A; Lu C
Cancer Invest; 2008 Jun; 26(5):535-42. PubMed ID: 18568776
[TBL] [Abstract][Full Text] [Related]
22. Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.
Venugopal C; Hallett R; Vora P; Manoranjan B; Mahendram S; Qazi MA; McFarlane N; Subapanditha M; Nolte SM; Singh M; Bakhshinyan D; Garg N; Vijayakumar T; Lach B; Provias JP; Reddy K; Murty NK; Doble BW; Bhatia M; Hassell JA; Singh SK
Clin Cancer Res; 2015 Dec; 21(23):5324-37. PubMed ID: 26152745
[TBL] [Abstract][Full Text] [Related]
23. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
[TBL] [Abstract][Full Text] [Related]
24. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.
Murat A; Migliavacca E; Gorlia T; Lambiv WL; Shay T; Hamou MF; de Tribolet N; Regli L; Wick W; Kouwenhoven MC; Hainfellner JA; Heppner FL; Dietrich PY; Zimmer Y; Cairncross JG; Janzer RC; Domany E; Delorenzi M; Stupp R; Hegi ME
J Clin Oncol; 2008 Jun; 26(18):3015-24. PubMed ID: 18565887
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
26. Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival.
Sprenger T; Conradi LC; Beissbarth T; Ermert H; Homayounfar K; Middel P; Rüschoff J; Wolff HA; Schüler P; Ghadimi BM; Rödel C; Becker H; Rödel F; Liersch T
Cancer; 2013 Jan; 119(1):26-35. PubMed ID: 22736392
[TBL] [Abstract][Full Text] [Related]
27. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors.
Yi JM; Tsai HC; Glöckner SC; Lin S; Ohm JE; Easwaran H; James CD; Costello JF; Riggins G; Eberhart CG; Laterra J; Vescovi AL; Ahuja N; Herman JG; Schuebel KE; Baylin SB
Cancer Res; 2008 Oct; 68(19):8094-103. PubMed ID: 18829568
[TBL] [Abstract][Full Text] [Related]
28. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme.
Pallini R; Ricci-Vitiani L; Banna GL; Signore M; Lombardi D; Todaro M; Stassi G; Martini M; Maira G; Larocca LM; De Maria R
Clin Cancer Res; 2008 Dec; 14(24):8205-12. PubMed ID: 19088037
[TBL] [Abstract][Full Text] [Related]
29. Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence.
Lin EH; Hassan M; Li Y; Zhao H; Nooka A; Sorenson E; Xie K; Champlin R; Wu X; Li D
Cancer; 2007 Aug; 110(3):534-42. PubMed ID: 17594720
[TBL] [Abstract][Full Text] [Related]
30. CD133 and BMI1 expressions and its prognostic role in primary glioblastoma.
Sibin MK; Lavanya CH; Bhat DI; Rao N; Geethashree N; Vibhuti W; Chetan GK
J Genet; 2015 Dec; 94(4):689-96. PubMed ID: 26690524
[TBL] [Abstract][Full Text] [Related]
31. High expression of octamer-binding transcription factor 4A, prominin-1 and aldehyde dehydrogenase strongly indicates involvement in the initiation of lung adenocarcinoma resulting in shorter disease-free intervals.
Cortes-Dericks L; Galetta D; Spaggiari L; Schmid RA; Karoubi G
Eur J Cardiothorac Surg; 2012 Jun; 41(6):e173-81. PubMed ID: 22529186
[TBL] [Abstract][Full Text] [Related]
32. Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy.
Weller M; Kaulich K; Hentschel B; Felsberg J; Gramatzki D; Pietsch T; Simon M; Westphal M; Schackert G; Tonn JC; von Deimling A; Davis T; Weiss WA; Loeffler M; Reifenberger G;
Int J Cancer; 2014 May; 134(10):2437-47. PubMed ID: 24614983
[TBL] [Abstract][Full Text] [Related]
33. Expression profiling of GIST: CD133 is associated with KIT exon 11 mutations, gastric location and poor prognosis.
Arne G; Kristiansson E; Nerman O; Kindblom LG; Ahlman H; Nilsson B; Nilsson O
Int J Cancer; 2011 Sep; 129(5):1149-61. PubMed ID: 21064103
[TBL] [Abstract][Full Text] [Related]
34. Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer.
Kim ST; Sohn I; DO IG; Jang J; Kim SH; Jung IH; Park JO; Park YS; Talasaz A; Lee J; Kim HC
Cancer Genomics Proteomics; 2014; 11(5):259-66. PubMed ID: 25331798
[TBL] [Abstract][Full Text] [Related]
35. Response of primary glioblastoma cells to therapy is patient specific and independent of cancer stem cell phenotype.
Fouse SD; Nakamura JL; James CD; Chang S; Costello JF
Neuro Oncol; 2014 Mar; 16(3):361-71. PubMed ID: 24311636
[TBL] [Abstract][Full Text] [Related]
36. Downregulation of Prominin 1/CD133 expression in colorectal cancer by NSAIDs following short-term preoperative treatment.
Lönnroth C; Andersson M; Nordgren S; Lundholm K
Int J Oncol; 2012 Jul; 41(1):15-23. PubMed ID: 22552364
[TBL] [Abstract][Full Text] [Related]
37. Enhanced MDR1 expression and chemoresistance of cancer stem cells derived from glioblastoma.
Nakai E; Park K; Yawata T; Chihara T; Kumazawa A; Nakabayashi H; Shimizu K
Cancer Invest; 2009 Nov; 27(9):901-8. PubMed ID: 19832037
[TBL] [Abstract][Full Text] [Related]
38. Girdin maintains the stemness of glioblastoma stem cells.
Natsume A; Kato T; Kinjo S; Enomoto A; Toda H; Shimato S; Ohka F; Motomura K; Kondo Y; Miyata T; Takahashi M; Wakabayashi T
Oncogene; 2012 May; 31(22):2715-24. PubMed ID: 22020337
[TBL] [Abstract][Full Text] [Related]
39. Stem cell marker CD133 affects clinical outcome in glioma patients.
Zeppernick F; Ahmadi R; Campos B; Dictus C; Helmke BM; Becker N; Lichter P; Unterberg A; Radlwimmer B; Herold-Mende CC
Clin Cancer Res; 2008 Jan; 14(1):123-9. PubMed ID: 18172261
[TBL] [Abstract][Full Text] [Related]
40. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma.
Liu G; Yuan X; Zeng Z; Tunici P; Ng H; Abdulkadir IR; Lu L; Irvin D; Black KL; Yu JS
Mol Cancer; 2006 Dec; 5():67. PubMed ID: 17140455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
